During the past five years, many states have imposed out-of-pocket spending caps on insulin. In most cases, these reforms have had limited impact, in part because of the limits of state authority. Meanwhile, changes at the federal level and actions by manufacturers and commercial plans have made some of the caps nonbinding. It is not surprising that efforts to measure the impact of these caps yield conflicting results.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1377/hlthaff.2024.00751 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!